HomeAbacavirAbacavir + Abacavir Sulfate Dolutegravir Sodium Lamivudine

Does Abacavir Interact with Abacavir Sulfate Dolutegravir Sodium Lamivudine?

Abacavir and Abacavir Sulfate Dolutegravir Sodium Lamivudine have a unknown drug interaction according to U.S. FDA drug labeling data. 7.3 Established and Other Potentially Significant Drug Interactions There were no drug-drug interaction trials conducted with the abacavir, dolutegravir, and lamivudine fixed-dose combination tablets. Methadone Abacavir: In a trial of 11 HIV-1–infected subjects receiving methadone-maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased [see Clinical Pharmacology ( 12.3 )] . Riociguat Abacavir: Coadministration with TRIUMEQ resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see Clinical Pharmacology ( 12.3 )] . Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Abacavir Sulfate Dolutegravir Sodium Lamivudine Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Abacavir and your doctor is considering prescribing Abacavir Sulfate Dolutegravir Sodium Lamivudine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Abacavir+💊 Abacavir Sulfate Dolutegravir Sodium Lamivudine(Triumeq)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Drug B class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Source
FDA drug label - abacavir sulfate, dolutegravir sodium, lamivudine

What this means in plain English

7.3 Established and Other Potentially Significant Drug Interactions There were no drug-drug interaction trials conducted with the abacavir, dolutegravir, and lamivudine fixed-dose combination tablets. Methadone Abacavir: In a trial of 11 HIV-1–infected subjects receiving methadone-maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased [see Clinical Pharmacology ( 12.3 )] . Riociguat Abacavir: Coadministration with TRIUMEQ resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see Clinical Pharmacology ( 12.3 )] .

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Abacavir and Abacavir Sulfate Dolutegravir Sodium Lamivudine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.